AI Develops Drug to Combat Aging

An American company utilizing artificial intelligence has successfully developed a drug for treating pulmonary fibrosis that demonstrated its ability to reduce biological aging markers. According to their published study, it lowered the biological age of volunteers by up to approximately four years. Although the study results are promising, researchers caution that they are not sufficient to definitively confirm the drug’s effectiveness, due to the small sample size and the inability to clearly separate the therapeutic effect from the reduction of aging signs directly. The study indicates that the drug helps improve indicators of biological age, but scientists continue to discuss the notion that aging is not a disease per se, and that drugs showing effects on biological age require more research to establish their efficacy.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل